{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:42Z","timestamp":1790740602060,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are no prospective studies to estimate whether cytology specimens can replace tissue samples using lung cancer gene panel analysis. We evaluated the success rate of gene panel testing and nucleic acid yield and quality when using cytology specimens for lung cancer over tissue specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective study, clinical cytology specimens collected via transbronchial brushing, needle aspiration washing, and pleural effusion were stored in a nucleic acid stabilizer. The primary endpoint was the superior success rate of gene analysis using cytology specimens over the conventional success rate using tissue specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The full analysis set included 248 cases. The success rate for gene panel analysis using cytology specimens was 98.4% (95% confidence interval (CI), 95.9\u201399.6%) with a positive concordance rate of 97.3% (95% CI, 90.7\u201399.7%) by other companion diagnostic kits. The median value for nucleic acid yield and quality (DNA\/RNA integrated number) of cytology specimens was 546.0\/426.5 ng and 9.2\/4.7 for DNA\/RNA, respectively. The Pearson correlation coefficient of variant allele frequency between tissue formalin-fixed and paraffin-embedded (FFPE) sample and cytology specimens for mutant cases was 0.815. The ratio of double-stranded to total DNA showed that cytology specimens were of significantly higher quality than FFPE specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The success rate of cytology specimens in gene analysis was significantly higher than conventional data. Because of the sufficient nucleic acid yield, high quality, and high correlation of mutant allele frequency compared to FFPE specimens, cytology specimens are suitable for panel testing as tissue substitutes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      UMIN Registry UMIN000047215 (cPANEL trial).\u00a0\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000053766\" ext-link-type=\"uri\">https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000053766<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-14770-0","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:20:34Z","timestamp":1760012434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prospective multicenter validation of a next-generation sequencing panel using cytology specimens for lung cancer: cPANEL"],"prefix":"10.1186","volume":"25","author":[{"given":"Kei","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Tsuzuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yokose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Mineshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"8","key":"14770_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2.","journal-title":"Nat Med"},{"issue":"7","key":"14770_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group. Ann Oncol. 2024;35(7):588\u2013606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005.","journal-title":"Ann Oncol"},{"key":"14770_CR3","unstructured":"FDA. Summary of safety and effectiveness data for Oncomine Dx Target Test; 2017. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160045B.pdf. Accessed March 27, 2022."},{"key":"14770_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/diagnostics11030391","volume":"11","author":"S Murakami","year":"2021","unstructured":"Murakami S, Yokose T, Nemoto D, Suzuki M, Usui R, Nakahara Y, et al. Suitability of bronchoscopic biopsy tissue samples for next-generation sequencing. Diagnostics. 2021;11:391.","journal-title":"Diagnostics"},{"key":"14770_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/resp.13823","volume":"25","author":"CK Liam","year":"2020","unstructured":"Liam CK, Mallawathantri S, Fong KM. Is tissue still the issue in detecting molecular alterations in lung cancer? Respirology. 2020;25:933\u201343.","journal-title":"Respirology"},{"key":"14770_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Besse B, Groen HJM, Mazieres J, Besse B, Helland \u00c5, et al. Dabrafenib plus Trametinib in patients with previously treated BRAF (V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984\u201393.","journal-title":"Lancet Oncol"},{"key":"14770_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cas.15176","volume":"113","author":"S Sakata","year":"2022","unstructured":"Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, et al. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: wjog 13019l. Cancer Sci. 2022;113:221\u20138.","journal-title":"Cancer Sci"},{"key":"14770_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/1759-7714.13743","volume":"12","author":"D Nemoto","year":"2021","unstructured":"Nemoto D, Yokose T, Katayama K, Murakami S, Kato T, Saito H, et al. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx target test in the analysis of biopsy tissue samples. Thorac Cancer. 2021;12:194\u2013200.","journal-title":"Thorac Cancer"},{"key":"14770_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/pin.13029","volume":"70","author":"T Kuwata","year":"2020","unstructured":"Kuwata T, Wakabayashi M, Hatanaka Y, Morii E, Oda Y, Taguchi K, et al. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN. Pathol Int. 2020;70:932\u201342.","journal-title":"Pathol Int"},{"key":"14770_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/1759-7714.13767","volume":"12","author":"T Sakaguchi","year":"2021","unstructured":"Sakaguchi T, Iketani A, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, et al. Comparison of the analytical performance between the Oncomine Dx target test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer. Thorac Cancer. 2021;12:462\u20137.","journal-title":"Thorac Cancer"},{"key":"14770_CR11","doi-asserted-by":"publisher","first-page":"e0290609","DOI":"10.1371\/journal.pone.0290609","volume":"18","author":"A Yatani","year":"2023","unstructured":"Yatani A, Katsurada N, Fukui T, Yamada J, Satoh H, Mimura C, et al. Diagnostic yield and the number of tumor cells of ultrathin bronchoscopy for peripheral lung lesions: a comparison with thin bronchoscopy. PLoS One. 2023;18:e0290609.","journal-title":"PLoS One"},{"key":"14770_CR12","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.3390\/cancers13235879","volume":"13","author":"K Uchimura","year":"2021","unstructured":"Uchimura K, Yanase K, Imabayashi T, Takeyasu Y, Furuse H, Tanaka M, et al. The impact of core tissues on successful next-generation sequencing analysis of specimens obtained through endobronchial ultrasound-guided transbronchial needle aspiration. Cancers (Basel). 2021;13:5879.","journal-title":"Cancers (Basel)"},{"key":"14770_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107190","volume":"179","author":"K Kunimasa","year":"2023","unstructured":"Kunimasa K, Matsumoto S, Kawamura T, Inoue T, Tamiya M, Kanzaki R, et al. Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung Cancer. 2023;179: 107190.","journal-title":"Lung Cancer"},{"key":"14770_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.lungcan.2017.07.015","volume":"111","author":"M Satouchi","year":"2017","unstructured":"Satouchi M, Tanaka H, Yoshioka H, Shimokawaji T, Mizuno K, Takeda K, et al. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas\u00ae EGFR mutation test. Lung Cancer. 2017;111:190\u20134.","journal-title":"Lung Cancer"},{"key":"14770_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/cncy.21322","volume":"121","author":"U Malapelle","year":"2013","unstructured":"Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathol. 2013;121:552\u201360.","journal-title":"Cancer Cytopathol"},{"key":"14770_CR16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jtho.2022.02.013","volume":"17","author":"D Jain","year":"2022","unstructured":"Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, et al. NSCLC subtyping in conventional cytology: results of the international association for the study of lung cancer cytology working group survey to determine specific cytomorphologic criteria for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol. 2022;17:793\u2013805.","journal-title":"J Thorac Oncol"},{"key":"14770_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Thorac Oncol. 2018;13:323\u201358.","journal-title":"J Thorac Oncol"},{"key":"14770_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0007-2017","volume":"26","author":"L Bubendorf","year":"2017","unstructured":"Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: number 2 in the series pathology for the clinician edited by Peter Dorfm\u00fcller and Alberto Cavazza. Eur Respir Rev. 2017;26: 170007.","journal-title":"Eur Respir Rev"},{"key":"14770_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.pathol.2023.08.002","volume":"55","author":"S Hendry","year":"2023","unstructured":"Hendry S, Mamotte L, Mesbah Ardakani N, Leslie C, Tesfai Y, Grieu-Iacopetta F, et al. Adequacy of cytology and small biopsy samples obtained with rapid onsite evaluation (ROSE) for predictive biomarker testing in non-small cell lung cancer. Pathology. 2023;55:917\u201321.","journal-title":"Pathology"},{"key":"14770_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000528346","volume":"90","author":"E Morii","year":"2023","unstructured":"Morii E, Hatanaka Y, Motoi N, Kawahara A, Hamakawa S, Kuwata T, et al. Guidelines for handling of cytological specimens in cancer genomic medicine. Pathobiology. 2023;90:289\u2013311.","journal-title":"Pathobiology"},{"key":"14770_CR21","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS One. 2022;17:e0264138.","journal-title":"PLoS One"},{"key":"14770_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial sloan Kettering-Integrated mutation profiling of actionable cancer targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251\u201364.","journal-title":"J Mol Diagn"},{"key":"14770_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/cncy.21868","volume":"125","author":"U Malapelle","year":"2017","unstructured":"Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, et al. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: a worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathol. 2017;125:615\u201326.","journal-title":"Cancer Cytopathol"},{"key":"14770_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cncy.22134","volume":"127","author":"P Pisapia","year":"2019","unstructured":"Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, et al. Consistency and reproducibility of next-generation sequencing in cytopathology: a second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathol. 2019;127:285\u201396.","journal-title":"Cancer Cytopathol"},{"key":"14770_CR25","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/cancers14153784","volume":"14","author":"K Morikawa","year":"2022","unstructured":"Morikawa K, Kida H, Handa H, Inoue T, Saji H, Koike J, et al. A prospective validation study of lung cancer gene panel testing using cytological specimens. Cancers. 2022;14:3784.","journal-title":"Cancers"},{"key":"14770_CR26","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/diagnostics13081476","volume":"13","author":"K Kato","year":"2023","unstructured":"Kato K, Okami J, Nakamura H, Honma K, Sato Y, Nakamura S, et al. Analytical performance of a highly sensitive system to detect gene variants using next-generation sequencing for lung cancer companion diagnostics. Diagnostics. 2023;13:1476.","journal-title":"Diagnostics"},{"key":"14770_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000527580","volume":"67","author":"FC Schmitt","year":"2023","unstructured":"Schmitt FC, Bubendorf L, Canberk S, Chandra A, Cree IA, Engels M, et al. The world health organization reporting system for lung cytopathology. Acta Cytol. 2023;67:80\u201391.","journal-title":"Acta Cytol"},{"key":"14770_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000520426","volume":"66","author":"A Yoshizawa","year":"2022","unstructured":"Yoshizawa A, Hiroshima K, Takenaka A, Haba R, Kawahara K, Minami Y, et al. Cytology reporting system for lung cancer from the Japan lung cancer society and the Japanese society of clinical cytology: an extensive study containing more benign lesions. Acta Cytol. 2022;66:124\u201333.","journal-title":"Acta Cytol"},{"key":"14770_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243\u201360.","journal-title":"J Thorac Oncol"},{"key":"14770_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12250-5","volume":"24","author":"C Mimura","year":"2024","unstructured":"Mimura C, Takamiya R, Fujimoto S, Fukui T, Yatani A, Yamada J, et al. Utility of bronchoscopically obtained frozen cytology pellets for next-generation sequencing. BMC Cancer. 2024;24: 489.","journal-title":"BMC Cancer"},{"key":"14770_CR31","doi-asserted-by":"publisher","first-page":"e1261","DOI":"10.1371\/journal.pone.0001261","volume":"2","author":"S Ahlfen","year":"2007","unstructured":"Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS One. 2007;2:e1261.","journal-title":"PLoS One"},{"key":"14770_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2041-2223-4-7","volume":"4","author":"SL Fordyce","year":"2013","unstructured":"Fordyce SL, Kampmann ML, van Doorn NL, Gilbert MT. Long-term RNA persistence in postmortem contexts. Investig Genet. 2013;4:7.","journal-title":"Investig Genet"},{"key":"14770_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/349431a0","volume":"349","author":"S Shibutani","year":"1991","unstructured":"Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature. 1991;349:431\u20134.","journal-title":"Nature"},{"key":"14770_CR34","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","volume":"11","author":"AB Schrock","year":"2016","unstructured":"Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11:1493\u2013502.","journal-title":"J Thorac Oncol"},{"key":"14770_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jmoldx.2016.09.006","volume":"19","author":"S Kim","year":"2017","unstructured":"Kim S, Park C, Ji Y, Kim DG, Bae H, van Vrancken M, et al. Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine. J Mol Diagn. 2017;19:137\u201346.","journal-title":"J Mol Diagn"},{"key":"14770_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520982687","volume":"49","author":"M Yuan","year":"2021","unstructured":"Yuan M, Wang Y, Yin W, Xiao Y, Hu M, Hu Y. Efficacy of rapid on-site cytological evaluation (ROSE) by a pulmonologist in determining specimen adequacy and diagnostic accuracy in interventional diagnosis of lung lesions. J Int Med Res. 2021;49: 300060520982687.","journal-title":"J Int Med Res"},{"key":"14770_CR37","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/jjco\/hyab059","volume":"51","author":"Y Takeyasu","year":"2021","unstructured":"Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, et al. Feasibility of next-generation sequencing (Oncomine\u2122 DX target test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Jpn J Clin Oncol. 2021;51:1114\u201322.","journal-title":"Jpn J Clin Oncol"},{"key":"14770_CR38","first-page":"100457","volume":"4","author":"V Hofman","year":"2022","unstructured":"Hofman V, Heeke S, Bontoux C, Chalabreysse L, Barritault M, Bringuier PP, et al. Ultrafast gene fusion assessment for nonsquamous NSCLC. JTO Clin Res Rep. 2022;4:100457.","journal-title":"JTO Clin Res Rep"},{"key":"14770_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/genes13050812","volume":"13","author":"K Morikawa","year":"2022","unstructured":"Morikawa K, Kinoshita K, Kida H, Inoue T, Mineshita M. Preliminary results of NGS gene panel test using NSCLC sputum cytology and therapeutic effect using corresponding molecular-targeted drugs. Genes. 2022;13:812.","journal-title":"Genes"},{"key":"14770_CR40","unstructured":"https:\/\/center6.umin.ac.jp\/cgi-openbin\/ctr_e\/ctr_view.cgi?recptno=R000059594"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14770-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:00:51Z","timestamp":1780390851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-14770-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14770"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14770-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6403904\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The license has been updated to CC-BY.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u30fbThe study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of St. Marianna University School of Medicine (approval number 5532).\u30fbWritten informed consent was obtained from all participants prior to study initiation.\u30fbThe study registered in the UMIN Registry (UMIN000047215) on March 18, 2022. An independent data-monitoring committee reviewed the clinical data.\u30fbAnimal Studies: N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have contributed significantly, and that all authors are in agreement with the content of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kei Morikawa reports financial support was provided by DNA Chip Research Inc, and received lecture fees as honoraria from Eli-Lilly, Chugai Pharmaceutical, Takeda Pharmaceutical, AstraZeneca K.K., Daiichi Sankyo, MSD, Nippon Boehringer Ingelheim Co., Ltd., and Bristol-Myers Squibb Japan. Yoshiharu Sato, Seiji Nakamura, Yumi Ueda, Fumihiko Suzuki reports a relationship with DNA Chip Research Inc that includes: employment and equity or stocks.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1538"}}